New type of anti-clotting drug reduces bleeding incidents among patients with atrial fibrillation

A new type of anti-clotting drug caused fewer bleeding incidents among patients with atrial fibrillation than the commonly prescribed apixaban, according to results from a head-to-head comparison of the two. The study, led by cardiologist at Duke Clinical Research Institute, was reported April 3 at the American College of Cardiology annual scientific sessions meeting and simultaneously published in the journal […]
Continue reading »